相似文献
1
Excessive activation of the complement system in atypical hemolytic uremic syndrome: is it ready for prime time?
Kidney Int. 2010 Feb;77(4):267-9. doi: 10.1038/ki.2009.467.
2
Atypical hemolytic uremic syndrome: update on the complement system and what is new.
Nephron Clin Pract. 2010;114(4):c219-35. doi: 10.1159/000276545. Epub 2010 Jan 14.
3
Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.
Clin J Am Soc Nephrol. 2013 Mar;8(3):407-15. doi: 10.2215/CJN.01260212. Epub 2012 Dec 14.
4
Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.
Kidney Int. 2010 Feb;77(4):339-49. doi: 10.1038/ki.2009.472. Epub 2009 Dec 16.
5
Atypical hemolytic uremic syndrome due to factor H autoantibody.
Turk J Pediatr. 2013 Jan-Feb;55(1):86-9.
6
Atypical hemolytic uremic syndrome.
Curr Opin Hematol. 2010 Sep;17(5):432-8. doi: 10.1097/MOH.0b013e32833cae86.
7
Thrombomodulin mutations in atypical hemolytic-uremic syndrome.
N Engl J Med. 2009 Jul 23;361(4):345-57. doi: 10.1056/NEJMoa0810739.
8
Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome.
Mol Immunol. 2008 Jan;45(1):95-105. doi: 10.1016/j.molimm.2007.05.004. Epub 2007 Jun 26.
9
Genetics and complement in atypical HUS.
Pediatr Nephrol. 2010 Dec;25(12):2431-42. doi: 10.1007/s00467-010-1555-5. Epub 2010 Jun 6.
10
Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.
J Am Soc Nephrol. 2013 Feb;24(3):475-86. doi: 10.1681/ASN.2012090884. Epub 2013 Feb 21.
本文引用的文献
1
Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.
Kidney Int. 2010 Feb;77(4):339-49. doi: 10.1038/ki.2009.472. Epub 2009 Dec 16.
2
Complement regulators and inhibitory proteins.
Nat Rev Immunol. 2009 Oct;9(10):729-40. doi: 10.1038/nri2620. Epub 2009 Sep 4.
3
Thrombomodulin mutations in atypical hemolytic-uremic syndrome.
N Engl J Med. 2009 Jul 23;361(4):345-57. doi: 10.1056/NEJMoa0810739.
4
Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation.
Blood. 2009 Sep 17;114(12):2439-47. doi: 10.1182/blood-2009-02-205641. Epub 2009 Jun 15.
5
The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.
J Med Genet. 2009 Jul;46(7):447-50. doi: 10.1136/jmg.2008.064766. Epub 2009 May 11.
6
Autoantibodies in haemolytic uraemic syndrome (HUS).
Thromb Haemost. 2009 Feb;101(2):227-32.
7
Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura.
Kidney Int Suppl. 2009 Feb(112):S11-4. doi: 10.1038/ki.2008.610.
8
Eculizumab for congenital atypical hemolytic-uremic syndrome.
N Engl J Med. 2009 Jan 29;360(5):544-6. doi: 10.1056/NEJMc0809959.
9
Eculizumab for atypical hemolytic-uremic syndrome.
N Engl J Med. 2009 Jan 29;360(5):542-4. doi: 10.1056/NEJMc0808527.
10
Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice.
J Clin Invest. 2008 Feb;118(2):608-18. doi: 10.1172/JCI32525.
Zotero 插件